טוען...
Safety and tolerability of once‐weekly GLP‐1 receptor agonists in type 2 diabetes
WHAT IS KNOWN AND OBJECTIVE: In recent years, glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) including once‐weekly (QW) formulations have been incorporated into type 2 diabetes (T2D) clinical guidelines, making it essential that pharmacists and healthcare professionals (HCPs) have a clear und...
שמור ב:
| הוצא לאור ב: | J Clin Pharm Ther |
|---|---|
| מחבר ראשי: | |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
John Wiley and Sons Inc.
2020
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7540535/ https://ncbi.nlm.nih.gov/pubmed/32910487 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/jcpt.13225 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|